

Role of ceramides in diabetic foot ulcers (Review)

YING WANG, ZHEN SUN, GUANGYAO ZANG, LILI ZHANG and ZHONGQUN WANG

Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China

Received September 9, 2022; Accepted January 20, 2023

DOI: 10.3892/ijmm.2023.5229

Abstract. Diabetes mellitus (DM) is a metabolic disorder, which if not managed properly, can lead to serious health problems over time and impose significant financial burden on the patient, their family and society as a whole. The study of this disease and the underlying biological mechanism is gaining momentum. Multiple pieces of conclusive evidence show that ceramides are involved in the occurrence and development of diabetes. The present review focuses on the function of ceramides, a type of sphingolipid signaling molecule, to provide a brief description of ceramides and their metabolism, discuss the significant roles of ceramides in the healthy skin barrier, and speculate on the potential involvement of ceramides in the pathogenesis and development of diabetic foot ulcers (DFUs). Understanding these aspects of this disease more thoroughly is crucial to establish how ceramides contribute to the etiology of diabetic foot infections and identify possible therapeutic targets for the treatment of DFUs.

Contents

1. Introduction
2. Biosynthesis and degradation of ceramides
3. Ceramides in the skin
4. Ceramides and DFUs
5. Ceramides and vessels
6. Ceramides and diabetes
7. Ceramides and atherosclerosis
8. Mechanism of ceramides in diabetes
9. Mechanism of ceramides in atherosclerosis
10. Shared mechanisms between diabetic complications and DFUs
11. Conclusions

1. Introduction

Diabetes mellitus (DM) is a metabolic disease characterized by three primary metabolic disorders, namely carbohydrate, lipid and protein metabolism disorders, all of which are caused by inadequate insulin production (1). Patients are usually diagnosed only when serious complications have occurred due to the ignorance of symptoms of diabetes in the early stages. Therefore, early detection, diagnosis and treatment can benefit a patient's health and quality of life, while also reducing the financial burden (2).

The complications of diabetes, including diabetic nephropathy, diabetic retinopathy, diabetic neuropathy (DN), cardiovascular complications, liver fibrosis and other complications, seriously affect the prognosis of diabetic patients (3). Diabetic foot ulcers (DFUs), one of the most prevalent and serious complications of diabetes (4), are common in diabetic patients and can lead to amputation or even death when the condition worsens (5).

Ceramides are a type of sphingolipid, the major lipid component of cell membranes (6). Ceramides not only act as the second messenger molecule in the sphingolipid signaling pathway, but also take part in the formation process of the stratum corneum. The stratum corneum, which is the primary portion of the intercellular matrix containing 40-50% of intercellular lipids, plays a crucial function in maintaining the water balance of the skin (7). Some studies have found that ceramides can inhibit glucose uptake and increase adipose ectopic deposition, while inhibiting the enzymes required for ceramide synthesis can improve the progression of diabetes (8-10). A single study has shown significant differences in the concentration of ceramides in the skin of the feet of diabetic and non-diabetic patients (11). Ceramides can be divided into several types according to their chemical composition. Different chemical structures correspond to different biological functions (12). Ceramides and their metabolites can decrease insulin sensitivity, blood vessel reactivity and pancreatic cell function, as well as maintaining the skin's barrier function, regulating hydration, exerting anti-aging effects and acting as future therapeutic targets for some diseases, such as insulin resistance, obesity, type 2 diabetes, Parkinson's disease, autoimmune rheumatic disease, ventilator-induced lung injury and cancer (especially breast cancer) (9,13-18).

All the aforementioned findings suggest that ceramides may have a close connection with the development of DFUs. The aim of the present review is to assess the role of ceramides in diabetes, the skin and atherosclerosis, and to discuss their

Correspondence to: Dr Zhongqun Wang, Department of Cardiology, Affiliated Hospital of Jiangsu University, 438 Jiefang Road, Jingkou, Zhenjiang, Jiangsu 212001, P.R. China
E-mail: wangtsmc@126.com

Key words: ceramides, diabetic foot ulcers, skin, atherosclerosis, diabetes mellitus

possible mechanisms in DFUs. The hope is that these findings will translate into new screening methods and treatments to alleviate and possibly prevent or cure diabetes and DFUs.

2. Biosynthesis and degradation of ceramides

Bioactive ceramides can be produced in three ways (6). First, the *de novo* pathway produces 3-keto-dihydrosphingosine by condensation of serine and palmitate catalyzed by serine palmitoyl transferase (SPT) (19). Next, sphinganine is N-acylated by six distinct ceramide synthases (CerSs) to form various dihydroceramides. The dihydroceramides are oxidized by dihydroceramide desaturase into corresponding ceramides. This is the main method of ceramide production (7).

Second, in the sphingomyelinase (SMase) pathway, ceramides are produced by hydrolysis of sphingomyelin (SM) catalyzed by SMases, which are divided into neutral SMases (nSMases 1, 2 and 3), acid SMases (aSMase) and alkaline SMases (20). When cellular stress occurs in a particular compartment, the level of ceramide is quickly increased multiple times through this pathway (21).

The third pathway is the salvage pathway, in which sphingolipids degraded to sphingosine (Sph) are reutilized by reacylation to produce ceramides. Lipid phosphate phosphatases or Sph-1-phosphate (S1P) phosphatase are used to obtain Sph (22). CerSs may acylate Sph to form ceramides. Ceramides can be digested by ceramidases in the opposite direction, resulting in Sph. Sph kinase (SphK) phosphorylates Sph, resulting in S1P, which then reenters sphingolipid metabolism by the SphK and/or one of the six CerSs (23) (Fig. 1).

Each CerS controls the production of endogenous ceramides from scratch. Although certain CerSs are found throughout the body, other isoforms create tissue-specific synthesis of ceramides. CerS1 specifically synthesizes C18 ceramide, and while it is highly expressed in the skeletal muscles, it is nearly undetectable in other tissues (24). CerS2 is mostly expressed in the kidneys and liver, and synthesizes C22-24 ceramides (25). Ceramides with varying acyl chain lengths may trigger diverse cell responses; hence, different CerS isoforms may create different ceramide species (17).

CerS3 is most highly expressed in the skin and synthesizes C28-C32 ceramides (26,27), CerS4 expression is not specific to any tissue and synthesizes C14-C16 ceramides, while CerS5 is primarily expressed in the epithelia of the lungs and CerS6 has been found in almost all tissues in the body, except in the intestines, spleen, lymph nodes and thymus (28). CerS5 and 6 specifically synthesize C14-C16 ceramides. CerS6 is primarily responsible for the production of C16 ceramides, which have been linked to a number of diseases, including insulin resistance and obesity (29).

Ceramides are broken down into free fatty acids (FFAs) and Sph by ceramidases. Five distinct ceramidases have been previously reported in humans, each with a different catalytic pH optimum, namely, acid ceramidase, neutral ceramidase, and alkaline ceramidases 1, 2 and 3, which are encoded by five separate genes (ASAH1, ASAH2, ACER1, ACER2 and ACER3, respectively) (30).

Ceramide species produced in the endoplasmic reticulum (ER) of the stratum spinosum inside the epidermis are subsequently acylated by linoleoyl-CoA to generate acyl-ceramides

in the skin. In healthy skin, the acyl chain length spans from C16 to C36, with C24 being the most common. Ceramides with distinct molecular architectures have different activities, implying that they play a variety of roles in skin homeostasis (31). Acyl-ceramides are glycosylated in the Golgi apparatus and subsequently transported with other lipids into lamellar bodies. The lamellar bodies, containing glycosylated ceramides, acyl ceramides, cholesterol and very-long-chain FAs, are secreted into the extracellular space of the stratum corneum, where the ceramides are covalently linked to structural skin proteins, such as involucrin, filaggrin and small proline-rich proteins, to form the epidermal permeability barrier (32).

3. Ceramides in the skin

Ceramide levels are significantly higher in insulin-resistant patients than in healthy individuals (33); therefore, the content level of the ceramides may be somehow related to skin disorders in diabetics. Ceramides containing omega carbons from linoleic acid esterified to omega hydroxy fatty acids are found only in the epidermis and help build a multilayered membrane that plays a key role in the skin barrier (34). The primary ceramides generated by the *de novo* pathway play a role in the development of the epidermal permeability barrier. The skin barrier is composed of extracellular ceramides. Intracellular ceramides, on the other hand, signal without O-acylation and have an acyl chain length of 16 to 18 carbon atoms (35).

Epidermal barrier structure. The skin of mammals serves as their body's first line of protection against external threats, making it one of the most important organs of the human body (36).

Both internal and external factors influence the epidermal ceramide expression profile. For example, downregulating CerS3 can reduce the proportion of unsaturated long-chain ceramides (37). Furthermore, AZGP1, an adipokine, has been shown to improve epidermal barrier function in Alzheimer's disease mice by increasing ceramide 3 (NP), ceramide 5 (AS) and ceramide 1 (EOS) (38).

The composition of ceramides in the stratum corneum is changing with age. Children have more ceramide 8 (NH), and less α -hydroxy and esterified ω -hydroxy ceramides than adults. There is less ceramide 1 in older people compared with that in younger people. Moreover, the degree of fatty acid chain saturation of ceramide 1 is associated with the season, being reduced in autumn and winter, which participates in lamellar and lateral lipid organization. Deficiency of this type of ceramide may be associated with seasonal skin dryness (39). Exposure to ultraviolet irradiation can increase plasma ceramide levels and decrease SM levels in mice (40). Therefore, the level of epidermal ceramides is maintained in dynamic equilibrium by control from a number of factors and plays an important role in skin homeostasis (41).

Although ceramides account for the highest proportion of skin lipids, they are no more important than other lipids. Previous studies found that perturbation of the skin with ceramides alone or mixtures of ceramides and FFAs




Figure 1. Three pathways for the synthesis of ceramides. There are three classical pathways for the synthesis of ceramides, namely the *de novo* pathway, the hydrolysis of sphingomyelin pathway and the salvage pathway. CerS, ceramide synthase; SM, sphingomyelin; SMase, sphingomyelinase; CD, ceramidase; S1P, sphingosine-1-phosphate; SPT, serine palmitoyltransferase; 3-KR, 3-ketosphinganine reductase.

delayed skin barrier recovery, and normal recovery was only possible with equimolar mixtures of all key lipids, as determined by transepidermal water loss (42,43). These findings

demonstrate that FFAs, cholesterol and ceramides are hydrophilic extracellular lipid matrices that are indispensable for skin permeability (44).

Despite the lack of direct evidence, ceramides have been hypothesized to regulate keratinocyte proliferation and differentiation in the skin. Both *in vitro* and *in vivo*, keratinocyte differentiation is reported to be accompanied by an increase in ceramide production (45).

Skin immune responses. Ceramides and their derivatives play a crucial role in controlling inflammation and the immune system. The activation of dendritic cells (DCs) with proinflammatory agents like lipopolysaccharide, TNF or interleukin 1 (IL1A and IL1B) has been shown to increase the intracellular concentrations of ceramides by promoting the stability of Toll-like receptor 4 (TLR4) (46). Changes in the transcriptional levels of ceramide synthetase and ceramidase in the lipid skeleton of TLR9-stimulated wild-type DCs were found to regulate the ceramide ratio (47). Ceramides are intracellular modulators of the NLR family, pyrin domain containing 3 (NLRP3) inflammasome assembly, and studies in microglia have shown that they can promote the release of IL1B (48). A single study has found that in mouse models, the presence of *Staphylococcus epidermidis* increases the content of ceramides in the epidermis by secreting SMase, which interferes with the growth of other pathogenic microorganisms and affects the immune pathway (49). Ceramides are therefore considered to be bioactive signaling molecules active in a number of inflammatory signaling pathways.

4. Ceramides and DFUs

One of the major chronic complications of diabetes, and the main cause of disability and mortality, is DFUs (50). Approximately 15-25% of diabetic patients will develop DFUs. Severe DFUs progress to gangrene and infection, leading to amputation (4). Despite the fact that DFUs can be treated, they can return up to 40% in the first year and almost 100% in the next decade (51). Numerous risk factors affect DFUs, but they are not independent causes of foot ulcers. Age, blood pressure, blood sugar levels, smoking, various types of nerve injury, impaired vascular circulation and diabetes over an extended period of time are all risk factors (52). DFUs are caused by peripheral neuropathy, peripheral artery disease, and repetitive external and minor trauma (Fig. 2) (53).

Ceramides, a crucial part of the keratinocyte membrane and a factor in the incidence and progression of several skin illnesses, are associated with the skin's barrier and permeability functions (35). Ceramides are also closely associated with insulin resistance, diabetes, and the microvascular and macrovascular side effects of diabetes, including atherosclerosis and DN (10). These findings raise the question of whether ceramides are crucial lipid molecules in diabetic patients who develop vascular disease, neuropathy and foot ulcers.

Pathophysiology of DFUs. The etiology of DFUs involves peripheral artery occlusive disease, neuropathy and trauma with subsequent infection (54).

DN included motor, peripheral and autonomic neuropathies (55). The manner in which diabetes causes DN is not clear. However, after the occurrence of DN, the muscles will atrophy, resulting in changes in the anatomical structure of the foot, and even the formation of deformities. Due to the

abnormal mechanical action, a foot hematoma occurs, which is mainly caused by motor neuropathy. Autonomic neuropathy causes blood vessels to dilate and the temperature of the foot to rise, drying out the skin and making it more vulnerable to damage. A lesion of the peripheral nerve makes the situation worse by depriving the patient of the protective sensation in the foot (56,57). Abnormal glucose metabolism occurs through the polyol and hexosamine pathways, leading to reactive oxygen species (ROS) production and inflammation through mitochondrial damage. In addition, abnormal glucose metabolism, resulting in glycosylation of proteins, the production of advanced glycation end products (AGEs), interaction with age-specific receptors and their own accumulation, can also lead to ROS production and the release of inflammatory factors. Similarly, excess free fat can also generate ROS through β -oxidative catabolism, causing local inflammation. The increase in ROS initiates the oxidative stress mechanism and causes tissue damage (58). Sphingolipid metabolism has been found to be associated with DN (59). The formation of abnormal deoxysphingolipids is harmful to pancreatic β -cells and nerve cells. Elevated levels of deoxysphingolipids have been found in patients with type 1 DM (T1DM) and T2DM with inherited sensory and autonomic neuropathy (60). Furthermore, these studies highlight the potential of plasma ceramide and deoxyceramide species as diagnostic and prognostic biomarkers for DN.

DM is now clearly associated with the development of cardiovascular disease (61). The vascular disease associated with DFUs is peripheral arterial disease of the lower extremity, which refers to an atherosclerotic occlusion from the main iliac artery to the foot artery (62). Hyperglycemia-induced epithelial dysfunction reduces pro-angiogenic signaling and nitric oxide (NO) production. NO prevents smooth muscle relaxation and leads to foot hypoperfusion, which can lead to an impaired skin barrier (63). Patients with diabetes are prone to atherosclerosis, resulting in poor blood perfusion in the foot and neuropathy making patients feel numb, coupled with repeated trauma and unreasonable pressure in daily life, so that the healing of the foot wound is delayed. This is followed by an infection of the foot, which can lead to gangrene and even amputation (64).

In addition, foot deformities, trauma and secondary infections accompanied by weakened resistance further aggravate DFUs, forming a vicious cycle (65).

5. Ceramides and vessels

Ceramides and the endothelium. Regulation of vascular tone requires the production of vasoactive substances, such as NO, by endothelial cells (66). According to the current evidence, ceramides have a detrimental effect on endothelial function. Endothelial dysfunction is caused by decreased NO synthesis or increased NO breakdown due to the generation of ROS (67). Ceramides can activate NADPH oxidase, increasing ROS, leading to increased oxidative stress, which degrades ceramidase (68). Ceramides have been shown to inhibit the *de novo* pathway of ceramides in diet-induced obese C57Bl/6 mice, which produces normalization of endothelial dysfunction and systemic hypertension (69). However, endothelium-dependent vasodilation is impaired when the

endothelium is briefly exposed to exogenous ceramides. This finding indicates that ceramides are crucial in the impairment of the endothelium caused by inflammation or obesity. Exogenous C16 ceramide-mediated endothelial NO synthase (NOS) uncoupling and dysregulated protein phosphatase 2 (PP2A) were found to damage human aortic endothelial cells in a study of atherosclerotic patients (70). Another study in patients with coronary arteries also found that ceramides were associated with coronary endothelial dysfunction (71). However, more mechanistic studies are needed to confirm the findings. Karakashian *et al* (72) demonstrated that nSMase activity persistently increases with aging, resulting in greater ceramide and endothelial NOS (eNOS) inactivation, as well as a reduction in NO production. In addition, nSMase-derived ceramides participate in the conversion of NO to H₂O₂, which leads to the reduction of NO and the formation of coronary artery disease (73). Ceramides have been shown to decrease eNOS3 (NOS3; also known as eNOS) activity, either under baseline conditions or after stimulation (74). On the other hand, in high-fat diet mice, inhibiting the synthesis of ceramides by the *de novo* pathway may indirectly improve endothelial dysfunction (75). Moreover, a research study has demonstrated that ceramides can activate NADPH oxidase (76), but other studies contend that ceramides can directly influence the mitochondrial electron transport chain to increase ROS in various cell types, including endothelial cells (77,78). Following a harmful self-amplifying cascade of events, the resultant O₂ can ultimately cause the decoupling of NOS3 and the generation of ROS in endothelial cells. Last but not least, ceramides have the ability to activate the NLRP3 inflammasomes and release inflammatory cytokines, thereby contributing to atherosclerotic lesions and vascular dysfunction (48).

Vasoactivity of ceramides. Ceramides have been found to be connected with vasoactivity. Ceramides can not only contract the blood vessels, but also vasodilate them (74). However, the mechanisms by which ceramides induce vasoactivity remain unclear.

A single study has shown that ceramide-induced vasodilation is partially endothelium-dependent via activation of NOS3 and subsequent NO generation, as aforementioned, by impairing endothelium function (79). Angiotensin II (ANGII) may indirectly increase ceramide production, thereby activating SMases in the peripheral vasculature to control vascular function (80).

However, a considerable amount of research has found that ceramides can promote vasoconstriction (74,81,82). Total ceramide levels in the aortic tissue of hypertensive rats and humans were much higher than those in normotensive mice and humans, with the main changes being increases in the levels of ceramides C24:1 and C24:0 (83). However, a correlation between increased blood pressure and increased ceramides in plasma does not indicate a causal relationship (84). Notably, it has been suggested that nSMase-derived ceramides promote the vasoconstriction caused by changes in the levels of thromboxane A₂, ANG II and oxygen tension (85,86).

In short, the vascular effects of ceramides appear to be complicated and remain unclear. This vasoactivity may be influenced by a variety of variables. Numerous exogenous and endogenous processes can produce ceramides, and can also

transform them into other active molecules. The different vascular effects may result from the different types of vessels and their various diameters, as well as the cell types they act on. Notably, different lengths of ceramides have different pathological functions (87).

6. Ceramides and diabetes

Diabetes and cardiovascular disease are mostly caused by lipotoxicity, an abnormal accumulation of lipids in non-adipose tissue. The most dangerous sphingolipids are those that promote cell death, insulin resistance and decreased insulin gene expression (88). A key component of the metabolism of sphingolipids is ceramides (29,30). Furthermore, previous studies have provided clear evidence that sphingolipids, particularly ceramides, have an important role in T1DM and the complications of T2DM (89,90). Indeed, several metabolic diseases, including DM, cardiomyopathy, insulin resistance and atherosclerosis, can be treated by preventing ceramide production or accelerating ceramide breakdown (87).

Ceramides and pancreatic β -cell apoptosis. TNF, IL1B and interferon γ are examples of inflammatory agents producing cytotoxicity to pancreatic β -cells by increasing the levels of sphingolipids, particularly ceramides, which are either exogenously delivered or produced endogenously (91). By contrast, several studies have shown that reducing ceramide production, such as inhibition of SPT or inhibition of CerS inhibitors, reduces cytotoxicity to rodent (92) and human (93) β -cells. In fact, there is evidence of a very small increase in ceramides following FFA therapy in trials involving cell apoptosis (94). However, some studies have shown that inhibiting ceramide synthesis reduces β -cell apoptosis (95-98). There may be three reasons to explain this result. First, the increased ceramide level induces apoptosis only at the designated site, namely the mitochondria, without changing the total ceramide mass (93). Second, upon triggering apoptosis, ceramides are changed into another sphingolipid metabolite (glucosylceramide) (99). Third, distinct ceramide isoforms may have different apoptotic potentials. In order to promote apoptosis, hyperglycemia increases the levels of the harmful isoforms of ceramides, namely C22:0, C24:1 and C18:0 (100).

Ceramides and insulin resistance. There is increasing evidence that ceramides play an important role in insulin resistance. Insulin resistance is a pathophysiological state characterized by hyperinsulinemia, high blood glucose levels and decreased responsiveness of peripheral tissues to insulin. Numerous studies have shown that excessive consumption of FFAs, the use of glucocorticoids, corpulence and decreased physical activity are some of the major contributors to insulin resistance, in which ceramides serve as a key intermediary (101). Increased ceramide accumulation from palmitate exposure occurs in several cells, including muscle cells (102), adipocytes (103) and cardiomyocytes (104). Simultaneous Akt inhibition results in decreased insulin sensitivity (105). Sphingolipid recycling or the salvage pathway can cause a buildup of ceramides in response to an excessive supply of saturated or unsaturated FAs. Ceramides are an obligatory intermediate in saturated FA-induced insulin resistance (101). Zalewska *et al* (106)

showed that mice administered a high-fat diet expressed higher levels of CerS than mice fed a regular diet. However, Holland *et al* (107) found that infusion of both highly saturated and highly unsaturated FAs reduced glucose uptake and Akt activation in rats, but infusion of highly saturated FAs alone increased ceramide levels. Both saturated fats and unsaturated fats can promote insulin resistance through different mechanisms, but ceramides only participate in saturated fat-induced insulin resistance (107). However, unsaturated FAs were not associated with increased levels of ceramides, which are not the only lipids responsible for insulin resistance. In line with this, overexpression of acid ceramidase can lower ceramide levels, prevent the buildup of ceramides caused by palmitate and enhance insulin signaling (108).

Glucocorticoids can increase the levels of ceramides, which may be the mechanism for inducing insulin resistance (107,109). By activating enzymes such as SPT, SMase and CerS, the commonly used glucocorticoid dexamethasone increases ceramide levels in a number of cell types and animal species, such as 3T3-L1 cells, wild-type mice and Sprague-Dawley rats (107,110,111). Pretreating C57Bl6/J mice with myriocin, a potent inhibitor of SPT, was shown to avoid some of these effects (112). However, the study involved a low dose of myriocin, so the alterations cannot be ruled out as a result of subsequent changes in the gut microbiota. Peroxisome proliferator-activated receptor α (PPARA) is activated by ceramide accumulation, and thus genetic disruption of PPARA, or other damage causing decreased hepatic PPARA expression, has been reported to inhibit insulin resistance in some conditions (113).

Obesity is known to contribute to T2DM by influencing glucose homeostasis and insulin sensitivity (114). However, the levels of ceramides in the skeletal muscles of rats, mice and diabetic patients have been reduced with long-term aerobic training (115,116). In other studies, for some unknown reason, even after exercise training in rats and people, the level of muscle ceramides does not significantly decrease (115,117,118).

7. Ceramides and atherosclerosis

Sphingolipids are bioactive lipids found in atherosclerotic plaques, which have been linked to both the development and progression of atherosclerosis. Although their specific effects in human atherosclerotic plaques are still unclear, ceramides are an important component in sphingolipids that are also associated with atherosclerosis (71). By promoting their aggregation through ceramide-ceramide interactions, SM may be converted to ceramides by aSMase on low-density lipoprotein (LDL) surfaces, thus accelerating the onset of atherosclerosis. Additionally, the pro-atherogenic pathways may be stimulated by the SIP produced from ceramides (119).

Ceramides from human plaques can cause plaque inflammation and cell death. Ceramide levels were higher in plaques connected to the inflammatory response, as determined by examining the histology and measuring cytokine levels of the plaques (120). Similar findings were obtained in mouse models (121).

Inhibiting SPT in the ceramide biosynthesis pathway with myriocin has been shown to decrease the progress of atherosclerosis in rodent models (122). Ceramides have been

shown to have more precise roles in the pathophysiology of cardiovascular disease than other existing lipid biomarkers, making them a promising biomarker for prediction purposes. Also, in mouse models, the inhibition of enzymes involved in ceramide synthesis can reduce cardiovascular complications. However, it is not easy to understand the possible mechanism of atherosclerosis without more research. On study found that ACER2 is a target gene for HIF-2 α , which reduces ceramide levels in fat cells and improves atherosclerosis (123). However, the study cannot rule out other mechanisms involved in protecting atherosclerosis.

8. Mechanism of ceramides in diabetes

Mechanism of ceramide-induced β -cell apoptosis. Due to its preservation of the integrity of the internal environment, apoptosis is described as genetically programmed cell death. The mechanism of apoptosis is complex. There are three known apoptotic signaling mechanisms: The intrinsic mitochondrial, intrinsic ER and extrinsic death receptor pathways. A number of studies have shown that ceramides are associated with the induction of β -cell apoptosis (124). Zhang *et al* (125) found that amyloid peptides induce β -cell apoptosis, partly through the production of ceramides by activating aSMase through activation of K⁺ channels on the cell membrane, which is a marker of cell apoptosis.

Ceramides have also been shown to cause apoptosis through their effect on the mitochondria, which controls regional levels of certain lipids like sphingolipids to detect cellular stress (126). BAX and ceramides work together to synergistically induce mitochondrial outer membrane permeabilization (MOMP). According to Ganesan *et al* (127), when ceramides are present, they are the key molecules in mitochondrial permeabilization, suggesting that the inhibition of ceramides without activating BAX-induced mitochondrial permeabilization, blocks the induction of MOMP, resulting in the death of yeast cells. According to the study by James *et al* (128), ceramides may be suggested in a new pathway leading to cell apoptosis by inducing the generation of Creola bodies, a marker of apoptotic lung epithelial cells. However, this was found in mouse lung tissues, and the mechanisms in other tissues require more investigation. Meanwhile, ROS also increased as a result of the increased ceramide level, which can contribute to apoptosis. Studies have found that ceramide-mediated insulin resistance-induced apoptosis was associated with the DNA-damage response and mitogen-activated protein kinase pathways, and that ceramides could mediate mitochondrial dysfunction (129,130). ROS are primarily produced by the mitochondria, and impairment of the mitochondria is generally considered to be associated with increased ROS. Apoptosis-inducing factors are generated when ceramides are being synthesized. Ceramides may inhibit the activation of mitochondrial NADPH oxidase, thus blocking electron transport at complex I and complex III of the respiratory chain, and inducing apoptosis by increasing ROS production (131,132).

Ceramides are a mediator of palmitate-induced cell toxicity, according to certain studies (133-135). One hypothesis that has been postulated is that ceramides can induce β -cell death by

activating protein kinase C δ -type (PKCD), which is necessary for apoptosis in numerous cell types (136).

Numerous studies have indicated that ER stress is crucial for cell apoptosis (137-139). During diabetes, insulin is produced in large amounts to counteract high blood sugar. In this situation, there is an increased burden on the ER, which serves as the location for the synthesis and folding of released proteins. The unfolded protein response (UPR), which aids in re-establishing normal ER function, is activated by ER stress (140). In addition, miR-204 has been found to activate the apoptotic signaling pathway in β -cells (141).

Another possible way to induce β -cell apoptosis is to inhibit the function of Akt, which is a serine/threonine kinase. First, it was shown that Akt could increase cellular proliferation, but that its inhibition could induce apoptosis (142). Second, Akt upregulates CDKN1B to trigger apoptosis while adversely regulating the transcriptional activity of FOXO1 (143). Third, Akt promotes mTOR/p70S6K signaling and directly phosphorylates and inactivates BCL2 members, including BAD, BAX and BID, to cause apoptosis (144). In addition, AKT induce apoptosis by activating cell signaling such as that of c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (98).

Mechanism of ceramide-induced insulin resistance. The phosphorylation of insulin receptor substrate-1 (IRS1), a mediator protein that links the binding of insulin and insulin growth factor 1 to related intracellular receptors of the insulin pathways, can activate ceramides to lead to impaired islet signaling (145). The increased IRS1 level induces serine 307 phosphorylation to inhibit insulin signaling (146). Ceramides can also suppress IRS1 expression by triggering the PKR/JNK/Prep1/p160 axis and/or the c-Jun amino-terminal kinase/PBX regulatory protein 1 axis (89). In addition, glucosylceramides have been demonstrated to impair insulin signaling by inhibiting insulin receptors (101,147).

As aforementioned, ceramides can inhibit AKT to cause β -cell apoptosis, and other studies have shown that they can also mediate the secretion of insulin (98,148,149). Ceramides first catalyze the dephosphorylation of AKT by activating PP2A (150). Ceramide secondly prevent the translocation of AKT to the PIP3-PDK1 complex in the plasma membrane. Ceramides can activate PKCZ (151), and then ceramide-induced phosphorylation inhibits this at the serine 473 or threonine 308 residue (24,102). This can form a stable AKT-PKCZ complex to prevent its interactions with PIP3. In further studies, PKC inhibitors were shown to improve insulin sensitivity and block the ceramide-induced loss of AKT activity (152-154). Ceramides were also elevated in other animal models such as Zucker diabetic fatty (ZDF) rats (155) and ob/ob mice (156), as well as in obese humans (157). If ceramides cause insulin resistance by inhibiting AKT, the proximal insulin signaling should be intact; however, there are also abnormalities in this proximal insulin signaling. In addition, the presence of the HIF-2 α -neuraminidase 3-ceramide pathway was also observed in mice administered a high-fat diet, and insulin sensitivity was improved in mice ablated with enteric-specific HIF-2 α . However, this only occurred in the absence of oxygen (158).

Exosome secretion and/or biogenesis may be impacted by ceramides. The protein adiponectin, which is released by adipocytes, stimulates the synthesis of exosomes in skeletal muscle and endothelial cells, and induces the expression of cadherin 13 (159). Given that research indicates that the microRNA profiles of exosomes were changed in patients with T2DM, Santovito *et al* (160) reported that exosomes, a metabolic mediator, produced by adipose tissue macrophages, impact insulin sensitivity in mice. Lean mice developed glucose intolerance and insulin resistance after exposure to exosomes from obese mice. By contrast, exosomes from adipose tissue macrophages in lean mice reduced insulin resistance and glucose intolerance in obese animals (161). Exosomes may also convert monocytes into macrophages, lead to inflammation and disrupt insulin signaling to cause T2DM (162).

9. Mechanism of ceramides in atherosclerosis

The most frequent cardiovascular consequence of T2DM is atherosclerosis, which develops in big and medium-sized arteries (163); it is characterized by inflammation, lipid and macrophage buildup, cell death and fibrosis (164). In addition, sphingolipids, including ceramides, are elevated in human atherosclerotic lesions, and it is widely recognized that chronic inflammation is the constant sign of T2DM and atherosclerosis (101). Additionally, sphingolipid metabolites are important in inflammatory signaling. Sphingolipids, particularly ceramides (the center of sphingolipid metabolism), have been proved to have an association with cell death, insulin resistance, inflammation and lipotoxicity, as previously described (6). The most prevalent and harmful metabolites in mammalian tissue are C16- and C18-ceramides (165). It was reported that ceramides cause inflammation in smooth muscle cells of the human coronary arteries (10). However, myriocin could suppress SPT by preventing ceramide *de novo* synthesis, which reduced atherosclerosis in apolipoprotein E-knockout mice (122). Atherosclerosis is also associated with lipoprotein aggregation. However, hydrolysis of SM to ceramides, especially nSMAes2, has been found to cause lipoprotein aggregation and participate in atherogenesis (166).

ER stress and the NLRP3 inflammasome have a close association with the development of atherosclerosis (167). As aforementioned, patients with T2DM may have defects in the downstream insulin signaling pathway that affect glucose transport due to activation of the IRS1 tyrosine phosphorylation/phosphoinositide 3 (PI-3) kinase axis (168). In addition, since the same PI-3 kinase pathway also activates NOS3, less NO is produced, which impairs endothelial function and accelerates atherosclerosis (169).

NFKB1B and NFKB are connected in the cytoplasm. Increased NFKB1B/NFKB signaling activity may be a significant factor in T2DM inflammation and insulin resistance (170). Fatty acyl-CoAs are an example of an inflammatory factor that activates NFKB1B kinase, phosphorylates NFKB1B and then translocates to the nucleus to bind to target genes, thus increasing the production of inflammatory cytokines that are involved in atherosclerosis (TNF, IL1B, IL6 and PKC) (171,172). Ceramides have the ability to activate certain plasma membrane receptors, including




Figure 3. Molecular mechanisms mediating DFUs in diabetes and atherosclerosis. Possible mechanisms of ceramides causing DFUs: i) Ceramides are associated with the induction of β -cell apoptosis by the activation of PKCD or by the inhibition of the function of AKT. ii) Ceramides inhibit insulin signaling via IRS1 by activating the PKR/JNK axis and/or Prepl/p160 axis or by GM3. iii) Ceramides activate PP2A and PKCZ to catalyze the dephosphorylation of AKT and then decrease the secretion of insulin. iv) Ceramides can affect exosome biogenesis and/or secretion to interfere with the downstream insulin signaling and inflammation through lipotoxicity. SMase, sphingomyelinase; Cer, ceramides; ER, endoplasmic reticulum; SM, sphingomyelin; IL, interleukin; PPA2, protein phosphatase 2; PKCD, protein kinase C δ -type; PKCZ, protein kinase C ζ -type; MVB, multivesicular body; Nlrp3, nucleotide-binding oligomerization domain-like receptor family, pyrin domain-containing 3; Prepl, PBX regulatory protein 1; PKR, dsRNA-activated protein kinase; JNK, c-Jun amino-terminal kinase; IR, insulin receptor; IRS, insulin receptor substrate; GM3, ganglioside GM3.

TLR4, which might lead to inflammation and insulin resistance (173). The TLR4 mRNA/protein levels are also elevated in the muscle of obese patients and those with T2DM, and they closely correspond with NFKB1B/NFKB activation, which is another mechanism for promoting atherosclerosis. Therefore, it is likely that ceramides are closely related to this development (174).

Since it has been shown that sphingolipid production is inhibited, atherosclerosis is reduced by the decreased expression of sterol-regulatory element binding transcription factors (SREBFs), which include SREBF1A, SREBF1C and SREBF2 (175). However, in animals orally treated with myriocin (an inhibitor of SPT and a necessary enzyme for the synthesis of ceramides), SREBF1C levels decreased, which

was potentially due to decreased very-LDL particle size. Myriocin was found to be anti-atherosclerotic. These effects may be partly correlated with SREBF (176,177).

In conclusion, ceramides are closely associated with diabetes and atherosclerosis, and the mechanism of action may involve the induction of DFUs (Fig. 3). Additional mechanisms of action of ceramides need to be found to support ceramides as the underlying molecule involved in the advent of DFUs.

10. Shared mechanisms between diabetic complications and DFUs

A certain degree of common pathogenesis is shared between diabetic complications and DFUs.

Diabetic nephropathy and diabetic retinopathy have the same pathogenesis, which is caused by the dysfunction of microvascular endothelial function (178). Consistent with DFUs, hyperglycemia through various pathways such as the polyol pathway, the AGE/receptor for AGE axis and the PKC pathway increases ROS production, causes oxidative stress and a series of inflammatory responses, and eventually leads to the accumulation of AGEs and endothelial dysfunction. At the same time, recent studies have found that renal cells can produce exosomes, which promote the development of inflammation and lead to endothelial cell damage (179-181). This is supported by the finding that the transplantation of new endothelial cells can prevent the development of a diabetic foot (182).

Diabetic peripheral neuropathy is involved in the development of DFUs, as aforementioned. The same diabetes leads to increased ROS levels and mitochondrial dysfunction, leading to impairment of axonal transport function in peripheral nerves, especially Schwann cells. However, the mechanism of diabetic peripheral neuropathy is still unclear (65).

Cardiac autonomic neuropathy and DFUs have also been recently linked, although the mechanism of cardiac autonomic neuropathy is still unclear. At present, ROS and AGEs are suspected to be associated with the occurrence of inflammation and microvascular lesions, which is also consistent with the occurrence of DFUs (183).

There is no evidence for a common mechanism of liver fibrosis and DFUs. In only one case report, excluding those on hepatitis and autoimmune liver diseases, was there a record of a patient with liver fibrosis that was associated with microangiopathy of the liver, as well as diabetic nephropathy and DFUs (184). This still needs more research and discussion.

11. Conclusions

Research has shown that ceramides are important in diabetes and cardiovascular disease. Ceramides are precursors of complex sphingolipids that form the epidermal barrier structure and are involved in maintaining skin homeostasis. Direct experimental evidence suggests that the plasma levels of ceramides are higher in diabetics, that ceramides antagonize insulin signaling, and that the inhibition or elimination of every ceramide biosynthesis-related enzyme is consistent with insulin sensitization, anti-atherosclerosis and heart protection. DFUs are a chronic complication of diabetes and an important cause of disability and death from diabetes, mainly caused by peripheral artery disease, peripheral neuropathy and recurrent external or mild trauma. Most of the existing reviews describe the association between ceramides and DM. The present review attempts to identify the function of ceramides in the occurrence and development of DFUs by elaborating on the association between ceramides and DM. The hope is that these findings will translate into new screening methods and treatments to alleviate and possibly prevent or cure diabetes and DFUs.

Acknowledgements

Not applicable.

Funding

This study was supported by the National Natural Science Foundation of China (grant no. 82070455), the related Foundation of Jiangsu Province (grant nos. BK20201225), the Medical Innovation Team Project of Jiangsu Province (grant no. CXTDA2017010).

Availability of data and materials

Not applicable.

Authors' contributions

YW conceived the topic and wrote the first draft. ZS, GZ, LZ and ZW revised the manuscript and figures. All authors read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H and Martín C: Pathophysiology of type 2 diabetes mellitus. *Int J Mol Sci* 21: 6275, 2020.
2. Zheng Y, Ley SH and Hu FB: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* 14: 88-98, 2018.
3. Demir S, Nawroth PP, Herzig S and Ekim Üstünel B: Emerging targets in type 2 diabetes and diabetic complications. *Adv Sci (Weinh)* 8: 2100275, 2021.
4. Everett E and Mathioudakis N: Update on management of diabetic foot ulcers: *Ann N Y Acad Sci* 1411: 153-165, 2018.
5. Wolf SJ, Melvin WJ and Gallagher K: Macrophage-mediated inflammation in diabetic wound repair. *Semin Cell Dev Biol* 119: 111-118, 2021.
6. Gomez-Larrauri A, Presa N, Dominguez-Herrera A, Ouro A, Trueba M and Gomez-Muñoz A: Role of bioactive sphingolipids in physiology and pathology. *Essays Biochem* 64: 579-589, 2020.
7. Castro BM, Prieto M and Silva LC: Ceramide: A simple sphingolipid with unique biophysical properties. *Prog Lipid Res* 54: 53-67, 2014.
8. Summers SA: Editorial: The role of ceramides in diabetes and cardiovascular disease. *Front Endocrinol (Lausanne)* 12: 667885, 2021.
9. Raichur S, Brunner B, Bielohuby M, Hansen G, Pfenninger A, Wang B, Bruning JC, Larsen PJ and Tennagels N: The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach. *Mol Metab* 21: 36-50, 2019.
10. Field BC, Gordillo R and Scherer PE: The role of ceramides in diabetes and cardiovascular disease regulation of ceramides by adipokines. *Front Endocrinol (Lausanne)* 11: 569250, 2020.
11. Lechner A, Akdeniz M, Tomova-Simitchieva T, Bobbert T, Moga A, Lachmann N, Blume-Peytavi U and Kottner J: Comparing skin characteristics and molecular markers of xerotic foot skin between diabetic and non-diabetic subjects: An exploratory study. *J Tissue Viability* 28: 200-209, 2019.

12. Summers SA, Chaurasia B and Holland WL: Metabolic messengers: Ceramides. *Nat Metab* 1: 1051-1058, 2019.
13. Custodia A, Aramburu-Núñez M, Correa-Paz C, Posado-Fernández A, Gómez-Larrauri A, Castillo J, Gómez-Muñoz A, Sobrino T and Ouro A: Ceramide metabolism and Parkinson's disease-therapeutic targets. *Biomolecules* 11: 945, 2021.
14. Alexandropoulou I, Grammatikopoulou MG, Gkouskou KK, Pritsa AA, Vassilakou T, Rigopoulou E, Lindqvist HM and Bogdanos DP: Ceramides in autoimmune rheumatic diseases: Existing evidence and therapeutic considerations for diet as an anticardamide treatment. *Nutrients* 15: 229, 2023.
15. Mandell EW and Savani RC: Ceramides, autophagy, and apoptosis mechanisms of ventilator-induced lung injury and potential therapeutic targets. *Am J Respir Crit Care Med* 199: 687-689, 2019.
16. Pal P, Atilla-Gokcumen GE and Frasier J: Emerging roles of ceramides in breast cancer biology and therapy. *Int J Mol Sci* 23: 11178, 2022.
17. Wattenberg BW: The long and the short of ceramides. *J Biol Chem* 293: 9922-9923, 2018.
18. Cha HJ, He C, Zhao H, Dong Y, An IS and An S: Intercellular and intracellular functions of ceramides and their metabolites in skin (Review). *Int J Mol Med* 38: 16-22, 2016.
19. Magnan C and Le Stunff H: Role of hypothalamic de novo ceramides synthesis in obesity and associated metabolic disorders. *Mol Metab* 53: 101298, 2021.
20. Insausti-Urkiá N, Solsona-Vilarrasa E, Garcia-Ruiz C and Fernandez-Checa JC: Sphingomyelinases and liver diseases. *Biomolecules* 10: 1497, 2020.
21. Taniguchi M and Okazaki T: Role of ceramide/sphingomyelin (SM) balance regulated through 'SM cycle' in cancer. *Cell Signal* 87: 110119, 2021.
22. Hammerschmidt P and Brüning JC: Contribution of specific ceramides to obesity-associated metabolic diseases. *Cell Mol Life Sci* 79: 395, 2022.
23. Bhattacharya N, Sato WJ, Kelly A, Ganguli-Indra G and Indra AK: Epidermal lipids: Key mediators of atopic dermatitis pathogenesis. *Trends Mol Med* 25: 551-562, 2019.
24. Roszczyc-Owsiejczuk K and Zabielski P: Sphingolipids as a culprit of mitochondrial dysfunction in insulin resistance and type 2 diabetes. *Front Endocrinol (Lausanne)* 12: 635175, 2021.
25. Aldoghachi AF, Baharudin A, Ahmad U, Chan SC, Ong TA, Yunus R, Razack AH, Yusoff K and Veerakumarasivam A: Evaluation of CERS2 gene as a potential biomarker for bladder cancer. *Dis Markers* 2019: 3875147, 2019.
26. Polubothu S, Glover M, Holder SE and Kinsler VA: Uniparental disomy as a mechanism for CERS3-mutated autosomal recessive congenital ichthyosis. *Br J Dermatol* 179: 1214-1215, 2018.
27. Sheridan M and Ogretmen B: The role of ceramide metabolism and signaling in the regulation of mitophagy and cancer therapy. *Cancers (Basel)* 13: 2475, 2021.
28. Kurz J, Parnham MJ, Geisslinger G and Schiffmann S: Ceramides as novel disease biomarkers. *Trends Mol Med* 25: 20-32, 2019.
29. Mullen TD, Hannun YA and Obeid LM: Ceramide synthases at the centre of sphingolipid metabolism and biology. *Biochem J* 441: 789-802, 2012.
30. Parveen F, Bender D, Law SH, Mishra VK, Chen CC and Ke LY: Role of ceramidases in sphingolipid metabolism and human diseases. *Cells* 8: 1573, 2019.
31. Li Q, Fang H, Dang E and Wang G: The role of ceramides in skin homeostasis and inflammatory skin diseases. *J Dermatol Sci* 97: 2-8, 2020.
32. Jung K, Kim SH, Joo KM, Lim SH, Shin JH, Roh J, Kim E, Park W and Kim W: Oral intake of enzymatically decomposed AP collagen peptides improves skin moisture and ceramide and natural moisturizing factor contents in the stratum corneum. *Nutrients* 13: 4372, 2021.
33. Ramírez-Vélez R, Martínez-Velilla N, Correa-Rodríguez M, Sáez de Asteasu ML, Zambom-Ferraresi F, Palomino-Echeverría S, García-Hermoso A and Izquierdo M: Lipidomic signatures from physically frail and robust older adults at hospital admission. *Geroscience* 44: 1677-1688, 2022.
34. Coderch L, López O, de la Maza A and Parra JL: Ceramides and skin function. *Am J Clin Dermatol* 4: 107-129, 2003.
35. Badhe Y, Gupta R and Rai B: Structural and barrier properties of the skin ceramide lipid bilayer: A molecular dynamics simulation study. *J Mol Model* 25: 140, 2019.
36. Vollmer DL, West VA and Lephart ED: Enhancing skin health: By oral administration of natural compounds and minerals with implications to the dermal microbiome. *Int J Mol Sci* 19: 3059, 2018.
37. Kim B, Shon JC, Seo HS, Liu KH, Lee JW, Ahn SK and Hong SP: Decrease of ceramides with long-chain fatty acids in psoriasis: Possible inhibitory effect of interferon gamma on chain elongation. *Exp Dermatol* 31: 122-132, 2022.
38. Wang L, Liu M, Ning D, Zhu H, Shan G, Wang D, Ping B, Yu Y, Yang H, Yan K, *et al*: Low serum ZAG levels correlate with determinants of the metabolic syndrome in Chinese subjects. *Front Endocrinol (Lausanne)* 11: 154, 2020.
39. Fujiwara A, Morifuji M, Kitade M, Kawahata K, Fukasawa T, Yamaji T, Itoh H and Kawashima M: Age-related and seasonal changes in covalently bound ceramide content in forearm stratum corneum of Japanese subjects: Determination of molecular species of ceramides. *Arch Dermatol Res* 310: 729-735, 2018.
40. Łuczaj W, Jastrzab A, do Rosário Domingues M, Domingues P and Skrzydlewska E: Changes in phospholipid/ceramide profiles and eicosanoid levels in the plasma of rats irradiated with UV rays and treated topically with cannabidiol. *Int J Mol Sci* 22: 8700, 2021.
41. Fujii M: The pathogenic and therapeutic implications of ceramide abnormalities in atopic dermatitis. *Cells* 10: 2386, 2021.
42. Meckfessel MH and Brandt S: The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products. *J Am Acad Dermatol* 71: 177-184, 2014.
43. Draelos ZD: The science behind skin care: Moisturizers. *J Cosmet Dermatol* 17: 138-144, 2018.
44. Wertz PW: Roles of lipids in the permeability barriers of skin and oral mucosa. *Int J Mol Sci* 22: 5229, 2021.
45. Bocheńska K and Gabig-Cimińska M: Unbalanced sphingolipid metabolism and its implications for the pathogenesis of psoriasis. *Molecules* 25: 1130, 2020.
46. Santinha DR, Marques DR, Maciel EA, Simões CS, Rosa S, Neves BM, Macedo B, Domingues P, Cruz MT and Domingues MR: Profiling changes triggered during maturation of dendritic cells: A lipidomic approach. *Anal Bioanal Chem* 403: 457-471, 2012.
47. Paget C, Deng S, Souldar D, Priestman DA, Specá S, von Gerichten J, Speak AO, Saroha A, Pevzner-Jung Y, Futerman AH, *et al*: TLR9-mediated dendritic cell activation uncovers mammalian ganglioside species with specific ceramide backbones that activate invariant natural killer T cells. *PLoS Biol* 17: e3000169, 2019.
48. Scheiblich H, Schlütter A, Golenbock DT, Latz E, Martínez-Martínez P and Heneka MT: Activation of the NLRP3 inflammasome in microglia: The role of ceramide. *J Neurochem* 143: 534-550, 2017.
49. Zheng Y, Hunt RL, Villaruz AE, Fisher EL, Liu R, Liu Q, Cheung GYC, Li M and Otto M: Commensal staphylococcus epidermidis contributes to skin barrier homeostasis by generating protective ceramides. *Cell Host Microbe* 30: 301-313.e9, 2022.
50. Wang Y, Shao T, Wang J, Huang X, Deng X, Cao Y, Zhou M and Zhao C: An update on potential biomarkers for diagnosing diabetic foot ulcer at early stage. *Biomed Pharmacother* 133: 110991, 2021.
51. Abbott CA, Chatwin KE, Foden P, Hasan AN, Sange C, Rajbhandari SM, Reddy PN, Vileikyte L, Bowling FL, Boulton AJM and Reeves ND: Innovative intelligent insole system reduces diabetic foot ulcer recurrence at plantar sites: A prospective, randomised, proof-of-concept study. *Lancet Digit Health* 1: e308-e318, 2019.
52. Kim EJ and Han K: Factors related to self-care behaviours among patients with diabetic foot ulcers. *J Clin Nurs* 29: 1712-1722, 2020.
53. Bandyk DF: The diabetic foot: Pathophysiology, evaluation, and treatment. *Semin Vasc Surg* 31: 43-48, 2018.
54. Aldana PC, Cartron AM and Khachemoune A: Reappraising diabetic foot ulcers: A focus on mechanisms of ulceration and clinical evaluation. *Int J Low Extrem Wounds* 21: 294-302, 2022.
55. Rubitschung K, Sherwood A, Crisologo AP, Bhavan K, Haley RW, Wukich DK, Castellino L, Hwang H, La Fontaine J, Chhabra A, *et al*: Pathophysiology and molecular imaging of diabetic foot infections. *Int J Mol Sci* 22: 11552, 2021.
56. Armstrong DG, Boulton AJM and Bus SA: Diabetic foot ulcers and their recurrence. *N Engl J Med* 376: 2367-2375, 2017.

57. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW and Viswanathan V: Diabetic neuropathy. *Nat Rev Dis Primers* 5: 42, 2019.
58. Volpe CMO, Villar-Delfino PH, dos Anjos PMF and Nogueira-Machado JA: Cellular death, reactive oxygen species (ROS) and diabetic complications. *Cell Death Dis* 9: 119, 2018.
59. Bönhof GJ, Herder C, Strom A, Papanas N, Roden M and Ziegler D: Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. *Endocr Rev* 40: 153-192, 2019.
60. Hammad SM, Baker NL, El Abiad JM, Spassieva SD, Pierce JS, Rembiesa B, Bielawski J, Lopes-Virella MF and Klein RL; DCCT/EDIC Group of Investigators: Increased plasma levels of select deoxy-ceramide and ceramide species are associated with increased odds of diabetic neuropathy in type 1 diabetes: A pilot study. *Neuromolecular Med* 19: 46-56, 2017.
61. Strain WD and Paldánus PM: Diabetes, cardiovascular disease and the microcirculation. *Cardiovasc Diabetol* 17: 57, 2018.
62. Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, McDermott MM, Misra S, Ujueta F; American Heart Association Council on Epidemiology and Prevention, *et al*: Lower extremity peripheral artery disease: Contemporary epidemiology, management gaps, and future directions: A scientific statement from the american heart association. *Circulation* 144: e171-e191, 2021.
63. He X and Schuchman EH: Ceramide and ischemia/reperfusion injury. *J Lipids* 2018: 3646725, 2018.
64. Davis FM, Kimball A, Boniakowski A and Gallagher K: Dysfunctional wound healing in diabetic foot ulcers: New crossroads. *Curr Diab Rep* 18: 2, 2018.
65. Sloan G, Selvarajah D and Tesfaye S: Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. *Nat Rev Endocrinol* 17: 400-420, 2021.
66. Zweier JL and Ilangovan G: Regulation of nitric oxide metabolism and vascular tone by cytoglobin. *Antioxid Redox Signal* 32: 1172-1187, 2020.
67. Sun HJ, Wu ZY, Nie XW and Bian JS: Role of endothelial dysfunction in cardiovascular diseases: The link between inflammation and hydrogen sulfide. *Front Pharmacol* 10: 1568, 2020.
68. Chabowski DS, Cohen KE, Abu-Hatoum O, Gutterman DD and Freed JK: Crossing signals: Bioactive lipids in the microvasculature. *Am J Physiol Heart Circ Physiol* 318: H1185-H1197, 2020.
69. Zhang QJ, Holland WL, Wilson L, Tanner JM, Kearns D, Cahoon JM, Pettey D, Losee J, Duncan B, Gale D, *et al*: Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. *Diabetes* 61: 1848-1859, 2012.
70. Akawi N, Checa A, Antonopoulos AS, Akoumianakis I, Daskalaki E, Kotanidis CP, Kondo H, Lee K, Yesilyurt D, Badi I, *et al*: Fat-secreted ceramides regulate vascular redox state and influence outcomes in patients with cardiovascular disease. *J Am Coll Cardiol* 77: 2494-2513, 2021.
71. Akhiyat N, Vasile V, Ahmad A, Sara JD, Nardi V, Lerman LO, Jaffe A and Lerman A: Plasma ceramide levels are elevated in patients with early coronary atherosclerosis and endothelial dysfunction. *J Am Heart Assoc* 11: e022852, 2022.
72. Karakashian AA, Giltiy NV, Smith GM and Nikolova-Karakashian MN: Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-beta-induced JNK activation. *FASEB J* 18: 968-970, 2004.
73. Parker BA, Walton CM, Carr ST, Andrus JL, Cheung ECK, Duplisea MJ, Wilson EK, Draney C, Lathen DR, Kenner KB, *et al*: β -Hydroxybutyrate elicits favorable mitochondrial changes in skeletal muscle. *Int J Mol Sci* 19: 2247, 2018.
74. Cogolludo A, Villamor E, Perez-Vizcaino F and Moreno L: Ceramide and regulation of vascular tone. *Int J Mol Sci* 20: 411, 2019.
75. Sletten AC, Peterson LR and Schaffer JE: Manifestations and mechanisms of myocardial lipotoxicity in obesity. *J Intern Med* 284: 478-491, 2018.
76. Arsenault EJ, McGill CM and Barth BM: Sphingolipids as regulators of neuro-inflammation and NADPH oxidase 2. *Neuromolecular Med* 23: 25-46, 2021.
77. Patwardhan GA, Beverly LJ and Siskind LJ: Sphingolipids and mitochondrial apoptosis. *J Bioenerg Biomembr* 48: 153-168, 2016.
78. Colombini M: Ceramide channels and mitochondrial outer membrane permeability. *J Bioenerg Biomembr* 49: 57-64, 2017.
79. Cantalupo A, Sasset L, Gargiulo A, Rubinelli L, Del Gaudio I, Benvenuto D, Wadsack C, Jiang XC, Buccì MR and Di Lorenzo A: Endothelial sphingolipid de novo synthesis controls blood pressure by regulating signal transduction and NO via ceramide. *Hypertension* 75: 1279-1288, 2020.
80. Pérez-Villavicencio R, Flores-Estrada J, Franco M, Escalante B, Pérez-Méndez O, Mercado A and Bautista-Pérez R: Effect of empagliflozin on sphingolipid catabolism in diabetic and hypertensive rats. *Int J Mol Sci* 23: 2883, 2022.
81. Lin YH, Jewell BE, Gingold J, Lu L, Zhao R, Wang LL and Lee DF: Osteosarcoma: Molecular pathogenesis and iPSC modeling. *Trends Mol Med* 23: 737-755, 2017.
82. Altura BM, Gebrewold A, Carella A, Shah NC, Shah GJ, Resnick LM and Altura BT: Why vasculitis probably can be ameliorated with magnesium and antagonists of ceramides and platelet-activating factor. *MOJ Anat Physiol* 6: 120-123, 2019.
83. Borodzicz-Jażdżyk S, Jażdżyk P, Łysik W, Cudnoch-Jędrzejewska A and Czarzasta K: Sphingolipid metabolism and signaling in cardiovascular diseases. *Front Cardiovasc Med* 9: 915961, 2022.
84. Zhang Y, Zhao H, Liu B, Shu H, Zhang L, Bao M, Yi W, Tan Y, Ji X, Zhang C, *et al*: Human serum metabolomic analysis reveals progression for high blood pressure in type 2 diabetes mellitus. *BMJ Open Diabetes Res Care* 9: e002337, 2021.
85. Li X, Wang HF, Li XX and Xu M: Contribution of acid sphingomyelinase to angiotensin II-induced vascular adventitial remodeling via membrane rafts/Nox2 signal pathway. *Life Sci* 219: 303-310, 2019.
86. Liu A, Chu YJ, Wang X, Yu R, Jiang H, Li Y, Zhou H, Gong LL, Yang WQ and Ju J: Serum metabolomics study based on LC-MS and antihypertensive effect of uncaria on spontaneously hypertensive rats. *Evid Based Complement Alternat Med* 2018: 9281946, 2018.
87. Shu H, Peng Y, Hang W, Li N, Zhou N and Wang DW: Emerging roles of ceramide in cardiovascular diseases. *Aging Dis* 13: 232-245, 2022.
88. Choi SR, Lim JH, Kim MY, Kim EN, Kim Y, Choi BS, Kim YS, Kim HW, Lim KM, Kim MJ and Park CW: Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy. *Metabolism* 85: 348-360, 2018.
89. Yaribeygi H, Bo S, Ruscica M and Sahebkar A: Ceramides and diabetes mellitus: An update on the potential molecular relationships. *Diabet Med* 37: 11-19, 2020.
90. Kane JP, Pullinger CR, Goldfine ID and Malloy MJ: Dyslipidemia and diabetes mellitus: Role of lipoprotein species and inter-related pathways of lipid metabolism in diabetes mellitus. *Curr Opin Pharmacol* 61: 21-27, 2021.
91. Guitton J, Bandet CL, Mariko ML, Tan-Chen S, Bourron O, Benomar Y, Hajdich E and Le Stunff H: Sphingosine-1-phosphate metabolism in the regulation of obesity/type 2 diabetes. *Cells* 9: 1682, 2020.
92. Miller LG Jr, Young JA, Ray SK, Wang G, Purohit S, Banik NL and Dasgupta S: Sphingosine toxicity in EAE and MS: Evidence for ceramide generation via serine-palmitoyltransferase activation. *Neurochem Res* 42: 2755-2768, 2017.
93. Siskind LJ: Mitochondrial ceramide and the induction of apoptosis. *J Bioenerg Biomembr* 37: 143-153, 2005.
94. Mancini A, Imperlini E, Nigro E, Montagnese C, Daniele A, Orrù S and Buono P: Biological and nutritional properties of palm oil and palmitic acid: Effects on health. *Molecules* 20: 17339-17361, 2015.
95. Park IB, Kim MH, Han JS and Park WJ: *Gryllus bimaculatus* extract protects against palmitate-induced β -cell death by inhibiting ceramide synthesis. *Appl Biol Chem* 65: 72, 2022.
96. Tong X, Chaudhry Z, Lee CC, Bone RN, Kanojia S, Maddatu J, Sohn P, Weaver SA, Robertson MA, Petrasche I, *et al*: Cigarette smoke exposure impairs β -cell function through activation of oxidative stress and ceramide accumulation. *Mol Metab* 37: 100975, 2020.
97. Xu YN, Wang Z, Zhang SK, Xu JR, Pan ZX, Wei X, Wen HH, Luo YS, Guo MJ and Zhu Q: Low-grade elevation of palmitate and lipopolysaccharide synergistically induced β -cell damage via inhibition of neutral ceramidase. *Mol Cell Endocrinol* 539: 111473, 2022.
98. Šrámek J, Němcová-Fürstová V and Kovář J: Molecular mechanisms of apoptosis induction and its regulation by fatty acids in pancreatic β -cells. *Int J Mol Sci* 22: 4285, 2021.
99. Canals D, Salamone S and Hannun YA: Visualizing bioactive ceramides. *Chem Phys Lipids* 216: 142-151, 2018.

100. Marra F and Svegliati-Baroni G: Lipotoxicity and the gut-liver axis in NASH pathogenesis. *J Hepatol* 68: 280-295, 2018.
101. Meikle PJ and Summers SA: Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. *Nat Rev Endocrinol* 13: 79-91, 2017.
102. Bandet CL, Tan-Chen S, Bourron O, Stunff HL and Hajdich E: Sphingolipid metabolism: New insight into ceramide-induced lipotoxicity in muscle cells. *Int J Mol Sci* 20: 479, 2019.
103. Fang Z, Pyne S and Pyne NJ: Ceramide and sphingosine 1-phosphate in adipose dysfunction. *Prog Lipid Res* 74: 145-159, 2019.
104. Bekhite M, González-Delgado A, Hübner S, Haxhikadrija P, Kretzschmar T, Müller T, Wu JMF, Bekfani T, Franz M, Wartenberg M, *et al*: The role of ceramide accumulation in human induced pluripotent stem cell-derived cardiomyocytes on mitochondrial oxidative stress and mitophagy. *Free Radic Biol Med* 167: 66-80, 2021.
105. Chavez JA, Knotts TA, Wang LP, Li G, Dobrowsky RT, Florant GL and Summers SA: A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. *J Biol Chem* 278: 10297-10303, 2003.
106. Zalewska A, Maciejczyk M, Szulimowska J, Imierska M and Błachnio-Zabielska A: High-fat diet affects ceramide content, disturbs mitochondrial redox balance, and induces apoptosis in the submandibular glands of mice. *Biomolecules* 9: 877, 2019.
107. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, *et al*: Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. *Cell Metab* 5: 167-179, 2007.
108. Petersen MC and Shulman GI: Mechanisms of insulin action and insulin resistance. *Physiol Rev* 98: 2133-2223, 2018.
109. Gasparini SJ, Swarbrick MM, Kim S, Thai LJ, Henneicke H, Cavanagh LL, Tu J, Weber MC, Zhou H and Seibel MJ: Androgens sensitise mice to glucocorticoid-induced insulin resistance and fat accumulation. *Diabetologia* 62: 1463-1477, 2019.
110. Linn SC, Kim HS, Keane EM, Andras LM, Wang E and Merrill AH Jr: Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. *Biochem Soc Trans* 29: 831-835, 2001.
111. Choi KM, Lee YS, Choi MH, Sin DM, Lee S, Ji SY, Lee MK, Lee YM, Yun YP, Hong JT and Yoo HS: Inverse relationship between adipocyte differentiation and ceramide level in 3T3-L1 cells. *Biol Pharm Bull* 34: 912-916, 2011.
112. Li Y, Talbot CL, Chandravanshi B, Ksiazek A, Sood A, Chowdhury KH, Maschek JA, Cox J, Babu AKS, Paz HA, *et al*: Cordyceps inhibits ceramide biosynthesis and improves insulin resistance and hepatic steatosis. *Sci Rep* 12: 7273, 2022.
113. Kumar DP, Caffrey R, Marioneaux J, Santhekadur PK, Bhat M, Alonso C, Koduru SV, Philip B, Jain MR, Giri SR, *et al*: The PPAR α/γ agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. *Sci Rep* 10: 9330, 2020.
114. Kucuk S, Niven J, Caamano J, Jones SW, Camacho-Muñoz D, Nicolaou A and Mauro C: Unwrapping the mechanisms of ceramide and fatty acid-initiated signals leading to immune-inflammatory responses in obesity. *Int J Biochem Cell Biol* 135: 105972, 2021.
115. Gilbert M: Role of skeletal muscle lipids in the pathogenesis of insulin resistance of obesity and type 2 diabetes. *J Diabetes Investig* 12: 1934-1941, 2021.
116. Reidy PT, Mahmassani ZS, McKenzie AI, Petrocelli JJ, Summers SA and Drummond MJ: Influence of exercise training on skeletal muscle insulin resistance in aging: Spotlight on muscle ceramides. *Int J Mol Sci* 21: 1514, 2020.
117. Coen PM and Goodpaster BH: Role of intramyocellular lipids in human health. *Trends Endocrinol Metab* 23: 391-398, 2012.
118. Galadari S, Rahman A, Pallichankandy S, Galadari A and Thayyullathil F: Role of ceramide in diabetes mellitus: Evidence and mechanisms. *Lipids Health Dis* 12: 98, 2013.
119. Choi RH, Tatum SM, Symons JD, Summers SA and Holland WL: Ceramides and other sphingolipids as drivers of cardiovascular disease. *Nat Rev Cardiol* 18: 701-711, 2021.
120. Edsfeldt A, Dunér P, Ståhlman M, Mollet IG, Ascittto G, Grufman AHM, Nitulescu M, Persson AF, Fisher RM, Melander O, *et al*: Proinflammatory role of sphingolipids and glycosphingolipids in the human atherosclerotic plaque. *Arterioscler Thromb Vasc Biol* 36: 1132-1140, 2016.
121. Wang P, Zeng G, Yan Y, Zhang SY, Dong Y, Zhang Y, Zhang X, Liu H, Zhang Z, Jiang C and Pang Y: Disruption of adipocyte HIF-1 α improves atherosclerosis through the inhibition of ceramide generation. *Acta Pharm Sin B* 12: 1899-1912, 2022.
122. Yang RX, Pan Q, Liu XL, Zhou D, Xin FZ, Zhao ZH, Zhang RN, Zeng J, Qiao L, Hu CX, *et al*: Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis. *Lipids Health Dis* 18: 179, 2019.
123. Zhang X, Zhang Y, Wang P, Zhang SY, Dong Y, Zeng G, Yan Y, Sun L, Wu Q, Liu H, *et al*: Adipocyte hypoxia-inducible factor 2 α suppresses atherosclerosis by promoting adipose ceramide catabolism. *Cell Metab* 30: 937-951.e5, 2019.
124. Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, Szulc ZM, Ruvolo P, Kornblau S, Andreeff M and Ogretmen B: Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. *Blood* 128: 1944-1958, 2016.
125. Zhang Y, Huang NQ, Yan F, Jin H, Zhou SY, Shi JS and Jin F: Diabetes mellitus and Alzheimer's disease: GSK-3 β as a potential link. *Behav Brain Res* 339: 57-65, 2018.
126. Yang Y, Xu G, Xu Y, Cheng X, Xu S, Chen S and Wu L: Ceramide mediates radiation-induced germ cell apoptosis via regulating mitochondria function and MAPK factors in caenorhabditis elegans. *Ecotoxicol Environ Saf* 208: 111579, 2021.
127. Ganesan V, Perera MN, Colombini D, Datskovskiy D, Chadha K and Colombini M: Ceramide and activated Bax act synergistically to permeabilize the mitochondrial outer membrane. *Apoptosis* 15: 553-562, 2010.
128. James BN, Oyeniran C, Sturgill JL, Newton J, Martin RK, Bieberich E, Weigel C, Maczys MA, Palladino END, Lownik JC, *et al*: Ceramide in apoptosis and oxidative stress in allergic inflammation and asthma. *J Allergy Clin Immunol* 147: 1936-1948.e9, 2021.
129. Römer A, Linn T and Petry SF: Lipotoxic impairment of mitochondrial function in β -cells: A review. *Antioxidants (Basel)* 10: 293, 2021.
130. Onyango AN: Cellular stresses and stress responses in the pathogenesis of insulin resistance. *Oxid Med Cell Longev* 2018: 4321714, 2018.
131. Ueda N: A rheostat of ceramide and sphingosine-1-phosphate as a determinant of oxidative stress-mediated kidney injury. *Int J Mol Sci* 23: 4010, 2022.
132. Poole LP and Macleod KF: Mitophagy in tumorigenesis and metastasis. *Cell Mol Life Sci* 78: 3817-3851, 2021.
133. Srivastava S and Chan C: Hydrogen peroxide and hydroxyl radicals mediate palmitate-induced cytotoxicity to hepatoma cells: Relation to mitochondrial permeability transition. *Free Radic Res* 41: 38-49, 2007.
134. Law BA, Liao X, Moore KS, Southard A, Roddy P, Ji R, Szulc Z, Bielawska A, Schulze PC and Cowart LA: Lipotoxic very-long-chain ceramides cause mitochondrial dysfunction, oxidative stress, and cell death in cardiomyocytes. *FASEB J* 32: 1403-1416, 2018.
135. Botta A, Elizbaryan K, Tashakorinia P, Lam NH and Sweeney G: An adiponectin-S1P autocrine axis protects skeletal muscle cells from palmitate-induced cell death. *Lipids Health Dis* 19: 156, 2020.
136. Simon JN, Chowdhury SAK, Warren CM, Sadayappan S, Wiczorek DF, Solaro RJ and Wolska BM: Ceramide-mediated depression in cardiomyocyte contractility through PKC activation and modulation of myofilament protein phosphorylation. *Basic Res Cardiol* 109: 445, 2014.
137. Kim C and Kim B: Anti-cancer natural products and their bioactive compounds inducing ER stress-mediated apoptosis: A review. *Nutrients* 10: 1021, 2018.
138. Hu H, Tian M, Ding C and Yu S: The C/EBP homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection. *Front Immunol* 9: 3083, 2019.
139. Xiang C, Wang Y, Zhang H and Han F: The role of endoplasmic reticulum stress in neurodegenerative disease. *Apoptosis* 22: 1-26, 2017.
140. Szpigel A, Hainault I, Carlier A, Venteclef N, Batto AF, Hajdich E, Bernard C, Ktorza A, Gautier JF, Ferré P, *et al*: Lipid environment induces ER stress, TXNIP expression and inflammation in immune cells of individuals with type 2 diabetes. *Diabetologia* 61: 399-412, 2018.
141. Xu G, Chen J, Jing G, Grayson TB and Shalev A: miR-204 targets PERK and regulates UPR signaling and β -cell apoptosis. *Mol Endocrinol* 30: 917-924, 2016.

142. Ojo OA, Grant S, Amanze JC, Oni AI, Ojo AB, Elebiyo TC, Obafemi TO, Ayokunle DI and Ogunlakin AD: Annona muricata L. peel extract inhibits carbohydrate metabolizing enzymes and reduces pancreatic β -cells, inflammation, and apoptosis via upregulation of PI3K/AKT genes. *PLoS One* 17: e0276984, 2022.
143. Wang Y, Liu J, Akatsu C, Zhang R, Zhang H, Zhu H, Liu K, Zhu HY, Min Q, Meng X, *et al*: LAPTM5 mediates immature B cell apoptosis and B cell tolerance by regulating the WWP2-PTEN-AKT pathway. *Proc Natl Acad Sci USA* 119: e2205629119, 2022.
144. Hsu CM, Lin JJ, Su JH and Liu CI: 13-Acetoxyarsocrossolidolide induces apoptosis in human hepatocellular carcinoma cells through mitochondrial dysfunction and suppression of the PI3K/AKT/mTOR/p70S6K signalling pathway. *Pharm Biol* 60: 2276-2285, 2022.
145. Cui F and He X: IGF-1 ameliorates streptozotocin-induced pancreatic β cell dysfunction and apoptosis via activating IRS1/PI3K/Akt/FOXO1 pathway. *Inflamm Res* 71: 669-680, 2022.
146. Denhez B, Rousseau M, Spino C, Dancosst DA, Dumas MÈ, Guay A, Lizotte F and Geraldes P: Saturated fatty acids induce insulin resistance in podocytes through inhibition of IRS1 via activation of both IKK β and mTORC1. *Sci Rep* 10: 21628, 2020.
147. Jennemann R, Kaden S, Volz M, Nordström V, Herzer S, Sandhoff R and Gröne HJ: Gangliosides modulate insulin secretion by pancreatic beta cells under glucose stress. *Glycobiology* 30: 722-734, 2020.
148. Benito-Vicente A, Jebari-Benslaïman S, Galicia-Garcia U, Larrea-Sebal A, Uribe KB and Martin C: Molecular mechanisms of lipotoxicity-induced pancreatic β -cell dysfunction. *Int Rev Cell Mol Biol* 359: 357-402, 2021.
149. Huang X, Liu G, Guo J and Su Z: The PI3K/AKT pathway in obesity and type 2 diabetes. *Int J Biol Sci* 14: 1483-1496, 2018.
150. Obanda DN, Ribnicky D, Yu Y, Stephens J and Cefalu WT: An extract of *Urtica dioica* L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A). *Sci Rep* 6: 22222, 2016.
151. Li J, Huang J, Lu J, Guo Z, Li Z, Gao H, Wang P, Luo W, Cai S, Hu Y, *et al*: Sirtuin 1 represses PKC- ζ activity through regulating interplay of acetylation and phosphorylation in cardiac hypertrophy. *Br J Pharmacol* 176: 416-435, 2019.
152. Ivey RA, Sajan MP and Farese RV: Requirements for pseudosubstrate arginine residues during autoinhibition and phosphatidylinositol 3,4,5-(PO₄)₃-dependent activation of atypical PKC. *J Biol Chem* 289: 25021-25030, 2014.
153. Campana M, Bellini L, Rouch C, Rachdi L, Coant N, Butin N, Bandet CL, Philippe E, Meneyrol K, Kassiss N, *et al*: Inhibition of central de novo ceramide synthesis restores insulin signaling in hypothalamus and enhances β -cell function of obese Zucker rats. *Mol Metab* 8: 23-36, 2018.
154. Wali JA, Jarzebska N, Raubenheimer D, Simpson SJ, Rodionov RN and O'Sullivan JF: Cardio-metabolic effects of high-fat diets and their underlying mechanisms-a narrative review. *Nutrients* 12: 1505, 2020.
155. Huang H, Aminian A, Hassan M, Dan O, Axelrod CL, Schauer PR, Brethauer SA and Kirwan JP: Gastric bypass surgery improves the skeletal muscle ceramide/SIP ratio and upregulates the AMPK/ SIRT1/ PGC-1 α pathway in Zucker diabetic fatty rats. *Obes Surg* 29: 2158-2165, 2019.
156. Matsuzaka T, Kuba M, Koyasu S, Yamamoto Y, Motomura K, Arulmozhiraja S, Ohno H, Sharma R, Shimura T, Okajima Y, *et al*: Hepatocyte ELOVL fatty acid elongase 6 determines ceramide Acyl-chain length and hepatic insulin sensitivity in mice. *Hepatology* 71: 1609-1625, 2020.
157. Yazıcı D and Sezer H: Insulin resistance, obesity and lipotoxicity. In: Engin AB and Engin A (eds). *Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology*. Vol. 960. Springer International Publishing, pp277-304, 2017.
158. Xia QS, Lu FE, Wu F, Huang ZY, Dong H, Xu LJ and Gong J: New role for ceramide in hypoxia and insulin resistance. *World J Gastroenterol* 26: 2177-2186, 2020.
159. Obata Y, Kita S, Koyama Y, Fukuda S, Takeda H, Takahashi M, Fujishima Y, Nagao H, Masuda S, Tanaka Y, *et al*: Adiponectin/T-cadherin system enhances exosome biogenesis and decreases cellular ceramides by exosomal release. *JCI Insight* 3: e99680, 2018.
160. Santovito D, De Nardis V, Marcantonio P, Mandolini C, Paganelli C, Vitale E, Buttitta F, Bucci M, Mezzetti A, Consoli A and Cipollone F: Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: Effect of glycemic control. *J Clin Endocrinol Metab* 99: E1681-E1685, 2014.
161. Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, Seo JB, Ofrecio JM, Wollam J, Hernandez-Carretero A, Fu W, *et al*: Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. *Cell* 171: 372-384. e12, 2017.
162. Tian F, Tang P, Sun Z, Zhang R, Zhu D, He J, Liao J, Wan Q and Shen J: miR-210 in exosomes derived from macrophages under high glucose promotes mouse diabetic obesity pathogenesis by suppressing NDUFA4 expression. *J Diabetes Res* 2020: 6894684, 2020.
163. Ruiz-León AM, Lapuente M, Estruch R and Casas R: Clinical advances in immunonutrition and atherosclerosis: A review. *Front Immunol* 10: 837, 2019.
164. Geovanini GR and Libby P: Atherosclerosis and inflammation: Overview and updates. *Clin Sci (Lond)* 132: 1243-1252, 2018.
165. Ho QWC, Zheng X and Ali Y: Ceramide Acyl chain length and its relevance to intracellular lipid regulation. *Int J Mol Sci* 23: 9697, 2022.
166. Sindhu S, Leung YH, Arefanian H, Madiraju SRM, Al-Mulla F, Ahmad R and Prentki M: Neutral sphingomyelinase-2 and cardiometabolic diseases. *Obes Rev* 22: e13248, 2021.
167. Chen X, Guo X, Ge Q, Zhao Y, Mu H and Zhang J: ER stress activates the NLRP3 inflammasome: A novel mechanism of atherosclerosis. *Oxid Med Cell Longev* 2019: 3462530, 2019.
168. Alaaeldin R, Abdel-Rahman IAM, Hassan HA, Youssef N, Allam AE, Abdelwahab SF, Zhao QL and Fathy M: Carpachromene ameliorates insulin resistance in HepG2 cells via modulating IR/IRS1/PI3k/Akt/GSK3/FoxO1 pathway. *Molecules* 26: 7629, 2021.
169. Gündüz D, Troidl C, Tanislav C, Rohrbach S, Hamm C and Aslam M: Role of PI3K/Akt and MEK/ERK signalling in cAMP/Epac-mediated endothelial barrier stabilisation. *Front Physiol* 10: 1387, 2019.
170. Prasad M, Gatasheh MK, Alshuniaber MA, Krishnamoorthy R, Rajagopal P, Krishnamoorthy K, Periyasamy V, Veeraraghavan VP and Jayaraman S: Impact of glyphosate on the development of insulin resistance in experimental diabetic rats: Role of NF κ B signalling pathways. *Antioxidants (Basel)* 11: 2436, 2022.
171. Wright CJ, McKenna S, De Dios R, Boehmer BH, Nguyen L, Ghosh S, Sandoval J and Rozance PJ: Lower threshold to NF κ B activity sensitizes murine β -cells to streptozotocin. *J Endocrinol* 249: 163-175, 2021.
172. Lin Z, Ge J, Wang Z, Ren J, Wang X, Xiong H, Gao J, Zhang Y and Zhang Q: Let-7e modulates the inflammatory response in vascular endothelial cells through ceRNA crosstalk. *Sci Rep* 7: 42498, 2017.
173. Olona A, Hateley C, Muralidharan S, Wenk MR, Torta F and Behmoaras J: Sphingolipid metabolism during Toll-like receptor 4 (TLR4)-mediated macrophage activation. *Br J Pharmacol* 178: 4575-4587, 2021.
174. Engin A: The pathogenesis of obesity-associated adipose tissue inflammation. In: *Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology*. Engin AB and Engin A (eds). Vol 960. Springer International Publishing, pp221-245, 2017.
175. Berg M, Polyzos KA, Agardh H, Baumgartner R, Forteza MJ, Kareinen I, Gisterå A, Bottcher G, Hurt-Camejo E, Hansson GK and Ketelhuth DFJ: 3-Hydroxyanthralinic acid metabolism controls the hepatic SREBP/lipoprotein axis, inhibits inflammation activation in macrophages, and decreases atherosclerosis in Ldlr $^{-/-}$ mice. *Cardiovasc Res* 116: 1948-1957, 2020.
176. Hornemann T and Worgall TS: Sphingolipids and atherosclerosis. *Atherosclerosis* 226: 16-28, 2013.
177. Dekker MJ, Baker C, Naples M, Samsouandar J, Zhang R, Qiu W, Sacco J and Adeli K: Inhibition of sphingolipid synthesis improves dyslipidemia in the diet-induced hamster model of insulin resistance: Evidence for the role of sphingosine and sphinganine in hepatic VLDL-apoB100 overproduction. *Atherosclerosis* 228: 98-109, 2013.
178. Yang J and Liu Z: Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy. *Front Endocrinol (Lausanne)* 13: 816400, 2022.
179. Sharma S, Schaper N and Rayman G: Microangiopathy: Is it relevant to wound healing in diabetic foot disease? *Diabetes Metab Res Rev* 36 (Suppl 1): e3244, 2020.
180. Wang S, Lei B, Zhang E, Gong P, Gu J, He L, Han L and Yuan Z: Targeted therapy for inflammatory diseases with mesenchymal stem cells and their derived exosomes: From basic to clinics. *Int J Nanomedicine* 17: 1757-1781, 2022.

181. Gil CL, Hooker E and Larrivéé B: Diabetic kidney disease, endothelial damage, and podocyte-endothelial crosstalk. *Kidney Med* 3: 105-115, 2020.
182. Zhao WN, Xu SQ, Liang JF, Peng L, Liu HL, Wang Z, Fang Q, Wang M, Yin WQ, Zhang WJ and Lou JN: Endothelial progenitor cells from human fetal aorta cure diabetic foot in a rat model. *Metabolism* 65: 1755-1767, 2016.
183. Basra R, Papanas N, Farrow F, Karalliedde J and Vas P: Diabetic foot ulcers and cardiac autonomic neuropathy. *Clin Ther* 44: 323-330, 2022.
184. King RJ, Harrison L, Gilbey SG, Santhakumar A, Wyatt J, Jones R and Bodansky HJ: Diabetic hepatosclerosis: Another diabetes microvascular complication? *Diabet Med* 33: e5-e7, 2016.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.